The research builds on previous scientific data from the lab of David C. Linehan, M.D., and may define a more personalized approach to treating pancreatic cancer. Ultimately, physicians will use information from the pancreas tumor biopsy about volume and predominance of cancer cells and non-cancerous inflammatory cells that impact the immune system, and then plan the best treatment. Read more . . .
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered that a three-drug combination can simultaneously target the cancer cells as well as the other harmful, inflammatory cells within the tumor, to improve survival.